Clinical Significance and Patterns of Potential Drug–Drug Interactions in Cardiovascular Patients: Focus on Low-Dose Aspirin and Angiotensin-Converting Enzyme Inhibitors
-
Published:2024-07-23
Issue:15
Volume:13
Page:4289
-
ISSN:2077-0383
-
Container-title:Journal of Clinical Medicine
-
language:en
-
Short-container-title:JCM
Author:
Anfinogenova Nina D.1ORCID, Stepanov Vadim A.2, Chernyavsky Alexander M.3, Karpov Rostislav S.1, Efimova Elena V.1, Novikova Oksana M.1, Trubacheva Irina A.1ORCID, Falkovskaya Alla Y.1, Maksimova Aleksandra S.1, Ryumshina Nadezhda I.1, Shelkovnikova Tatiana A.1ORCID, Ussov Wladimir Y.13ORCID, Vaizova Olga E.4, Popov Sergey V.1, Repin Alexei N.1
Affiliation:
1. Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634012 Tomsk, Russia 2. Research Institute of Medical Genetics, Tomsk National Research Medical Center, Russian Academy of Sciences, 634050 Tomsk, Russia 3. Meshalkin National Medical Research Center, 630055 Novosibirsk, Russia 4. Siberian State Medical University, Ministry of Health of the Russian Federation, 634050 Tomsk, Russia
Abstract
Objective: This study assessed the patterns and clinical significance of potential drug–drug interactions (pDDIs) in patients with diseases of the cardiovascular system. Methods: Electronic health records (EHRs), established in 2018–2023, were selected using the probability serial nested sampling method (n = 1030). Patients were aged 27 to 95 years (65.0% men). Primary diagnosis of COVID-19 was present in 17 EHRs (1.7%). Medscape Drug Interaction Checker was used to characterize pDDIs. The Mann–Whitney U test and chi-square test were used for statistical analysis. Results: Drug numbers per record ranged from 1 to 23 in T-List and from 1 to 20 in P-List. In T-List, 567 drug combinations resulted in 3781 pDDIs. In P-List, 584 drug combinations resulted in 5185 pDDIs. Polypharmacy was detected in 39.0% of records in T-List versus 65.9% in P-List (p-value < 0.05). The rates of serious and monitor-closely pDDIs due to ‘aspirin + captopril’ combinations were significantly higher in P-List than in T-List (p-value < 0.05). The rates of serious pDDIs due to ‘aspirin + enalapril’ and ‘aspirin + lisinopril’ combinations were significantly lower in P-List compared with the corresponding rates in T-List (p-value < 0.05). Serious pDDIs due to administration of aspirin with fosinopril, perindopril, and ramipril were detected less frequently in T-List (p-value < 0.05). Conclusions: Obtained data may suggest better patient adherence to ‘aspirin + enalapril’ and ‘aspirin + lisinopril’ combinations, which are potentially superior to the combinations of aspirin with fosinopril, perindopril, and ramipril. An abundance of high-order pDDIs in real-world clinical practice warrants the development of a decision support system aimed at reducing pharmacotherapy-associated risks while integrating patient pharmacokinetic, pharmacodynamic, and pharmacogenetic information.
Funder
Russian Science Foundation state assignment for basic research
Reference79 articles.
1. Global and regional prevalence of multimorbidity in the adult population in community settings: A systematic review and meta-analysis;Chowdhury;EClinicalMedicine,2023 2. Medical error-the third leading cause of death in the US;Makary;BMJ,2016 3. Anfinogenova, N.D., Novikova, O.M., Trubacheva, I.A., Efimova, E.V., Chesalov, N.P., Ussov, W.Y., Maksimova, A.S., Shelkovnikova, T.A., Ryumshina, N.I., and Stepanov, V.A. (2023). Prescribed versus taken polypharmacy and drug-drug interactions in older cardiovascular patients during the COVID-19 pandemic: Observational cross-sectional analytical study. J. Clin. Med., 12. 4. Dornquast, C., Dombrowski, M., Zabel, M., Willich, S.N., and Reinhold, T. (2020). Potential drug-drug interactions in patients with indication for prophylactic implantation of a cardioverter defibrillator: A cross-sectional analysis. BMC Health Serv. Res., 20. 5. Potentially Harmful Drug-Drug Interactions and Their Associated Factors Among Hospitalized Cardiac Patients: A Cross-Sectional Study;Kalash;Drugs-Real World Outcomes,2023
|
|